Rasamsonia argillacea species complex: Taxonomy, pathogenesis and clinical relevance

Future Microbiology

Volumn 8, Issue 8, 2013, Pages 967-978

  Giraud, Sandrine ^a   Favennec, Loïc ^b   Bougnoux, Marie Elisabeth ^c   Bouchara, Jean Philippe ^a,d  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

chronic granulomatous disease; cystic fibrosis; filamentous fungi; Geosmithia argillacea; German shepherd dog; graft versus host disease; Rasamsonia argillacea species complex; thermotolerance

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; COLISTIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ATOPIC DERMATITIS; CHRONIC GRANULOMATOUS DISEASE; CYSTIC FIBROSIS; FUNGAL COLONIZATION; FUNGUS; GEOGRAPHIC DISTRIBUTION; HEAT TOLERANCE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PAECILOMYCES; PATHOGENESIS; PENICILLIUM; PNEUMONIA; PRIORITY JOURNAL; RASAMSONIA ARGILLACEA; REVIEW; TAXONOMY;

CYSTIC FIBROSIS; DRUG RESISTANCE, FUNGAL; EUROTIALES; FUNGEMIA; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; LUNG DISEASES, FUNGAL; MICROBIOLOGICAL TECHNIQUES; MYCOSES; RISK FACTORS;

EID: 84881297014     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.63     Document Type: Review

References (79)

1. Stolk A, Evans H, Nilsson T. Penicillium argillaceum sp. nov. a thermotolerant Penicillium. Trans. Br. Mycol. Soc. 53 (2), 307-311 (1969).
2. Pitt J. Geosmithia gen. nov. for Penicillium lavendulum and related species. Can. J. Bot. 57 (19), 2021-2030 (1979).
3. Ogawa H, Yoshimura A, Sugiyama J. Polyphyletic origins of species of the anamorphic genus Geosmithia and the relationships of the cleistothecial genera: Evidence from 18S, 5S and 28S rDNA sequence analyses. Mycologia 89 (5), 756-771 (1997).
4. Kolarik M, Kubatova A, Pazoutova S, Srutka P. Morphological and molecular characterisation of Geosmithia putterillii, G. pallida comb. nov. and G. flava sp. nov., associated with subcorticolous insects. Mycol. Res. 108 (Pt 9), 1053-1069 (2004).
5. Kolarik M, Kostovcik M, Pazoutova S. Host range and diversity of the genus Geosmithia (Ascomycota: Hypocreales) living in association with bark beetles in the Mediterranean area. Mycol. Res. 111 (Pt 11), 1298-1310 (2007).
6. Kolarik M, Kubatova A, Hulcr J, Pazoutova S. Geosmithia fungi are highly diverse and consistent bark beetle associates: Evidence from their community structure in temperate Europe. Microb. Ecol. 55 (1), 65-80 (2008).
7. Kolarik M, Kirkendall LR. Evidence for a new lineage of primary ambrosia fungi in Geosmithia Pitt (Ascomycota: Hypocreales). Fungal Biol. 114 (8), 676-689 (2010).
8. Yaguchi T, Edagawa S, Nishimura K. Geosmithia argillacea is the anamorph of Talaromyces eberneus as a heat resistant fungus. Cryptogam. Mycol. 26 (2), 131-141 (2005).
9. Prieto A, Ahrazem O, Gomez-Miranda B, Bernabe M, Leal JA. Cell wall polysaccharides F1SS disclose the relatedness of the genus Geosmithia with Eupenicillium and Talaromyces. Can. J. Bot. 80 (4), 410-415 (2002).
10. Houbraken J, Spierenburg H, Frisvad JC. Rasamsonia, a new genus comprising thermotolerant and thermophilic Talaromyces and Geosmithia species. Antonie Van Leeuwenhoek 101 (2), 403-421 (2012).
11. Norvell LL. Melbourne approves a new code. Mycotaxon, 116, 481-490 (2011).
12. Su Y, Cai L. Rasamsonia composticola, a new thermophilic species isolated from compost in Yunnan, China. Mycol. Prog. 12 (2) 213-221 (2012).
13. Houbraken J, Giraud S, Meijer M et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J. Clin. Microbiol. 51 (1), 22-30 (2013).
14. Del Chierico F, Masotti A, Onori M et al. MALDI-TOF MS proteomic phenotyping of filamentous and other fungi from clinical origin. J. Proteomics 75 (11), 3314-3330 (2012).
15. Grant DC, Sutton DA, Sandberg CA et al. Disseminated Geosmithia argillacea infection in a German shepherd dog. Med. Mycol. 47 (2), 221-226 (2009).
16. Giraud S, Pihet M, Razafimandimby B et al. Geosmithia argillacea: An emerging pathogen in patients with cystic fibrosis. J. Clin. Microbiol. 48 (7), 2381-2386 (2010).
17. Barton RC, Borman AM, Johnson EM et al. Isolation of the fungus Geosmithia argillacea in sputum of people with cystic fibrosis. J. Clin. Microbiol. 48 (7), 2615-2617 (2010).
18. Valentin T, Neumeister P, Pichler M et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant. 47 (5), 734-736 (2012).
19. De Ravin SS, Challipalli M, Anderson V et al. Geosmithia argillacea: An emerging cause of invasive mycosis in human chronic granulomatous disease. Clin. Infect. Dis. 52 (6), e136-e143 (2011).
20. Machouart M, Garcia-Hermoso D, Rivier A et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J. Clin. Microbiol. 49 (4), 1681-1683 (2011).
21. Doyon JB, Sutton DA, Theodore P et al. Rasamsonia argillacea pulmonary and aortic graft infection in an immune competent patient. J. Clin. Microbiol. 51 (2), 719-722 (2013).
22. Jang JH, Lee JH, Ki CS, Lee NY. Identification of clinical mold isolates by sequence analysis of the internal transcribed spacer region, ribosomal large-subunit D1/D2, and b-tubulin. Ann. Lab. Med. 32 (2), 126-132 (2012).
23. Marguet C, Favennec L, Matray O et al. Clinical and microbiological efficacy of micafungin on Geosmithia argillacea infection in a cystic fibrosis patient. Med. Mycol. Case Rep. 1 (1), 79-81 (2012).
24. Manso E, Cariani L, Fiscarelli E et al. Isolation of filamentous fungi in the sputum of cystic fibrosis patients in Italy: State of the art and epidemiology. Presented at: 2nd Meeting of the ECMM/ISHAM Working Group Fungal Respiratory Infections in Cystic Fibrosis (Fri-CF). Angers, France, 1-2 September 2011.
25. Steinmann J, Hamprech A, Sedlacek L, Schmidt D, Buer J, Rath PM. Phenotypic and genotypic characteristics of Geosmithia argillacea. Mycoses 55 (Suppl.4), 216 (2012).
26. Terpstra PDP, Westreenen MV, Croughs P et al. Epidemiology of filamentous fungi in cystic fibrosis patients in The Netherlands. Mycoses 55 (Suppl. 4), 93 (2012).
27. Day MJ, Eger CE, Shaw SE, Penhale WJ. Immunologic study of systemic aspergillosis in German shepherd dogs. Vet. Immunol. Immunopathol. 9 (4), 335-347 (1985).
28. Schemuth H, Dittmer S, Lackner M et al. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses 56 (3), 297-303 (2012).
29. Li J, Nation RL, Turnidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6 (9), 589-601 (2006).
30. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40 (9), 1333-1334 (2005); erratum: 42 (12), 1819 (2006).
31. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J. Antimicrob. Chemother. 57 (6), 1251-1254 (2006).
32. Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57 (2), 306-311 (2006).
33. Antoniu SA, Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin. Drug Deliv. 9 (3), 333-342 (2012).
34. Moore JE, Elborn JS. Implications for colistin use in patients with cystic fibrosis (CF): Letter in response to 'Prophylactic and metaphylactic antimicrobial use in Belgian fattening pig herds' by Callens et al. [Prev. Vet. Med. 106 (2012) 53-62]. Prev. Vet. Med. 107 (3-4), 286-287; author reply 288-290 (2012).
35. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: A review of the infectious and inflammatory complications. Clin. Mol. Allergy 9 (1), 10-23 (2011).
36. Baehner RL, Karnovsky ML. Deficiency of reduced nicotinamide-adenine dinucleotide oxidase in chronic granulomatous disease. Science (New York, NY) 162 (3859), 1277-1279 (1968).
37. Baehner RL, Nathan DG. Quantitative nitroblue tetrazolium test in chronic granulomatous disease. N. Engl. J. Med., 278 (18), 971-976 (1968).
38. Ahlin A, De Boer M, Roos D et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr. 84 (12), 1386-1394 (1995).
39. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur. J. Pediatr. 166 (11), 1099-1117 (2007).
40. Alsultan A, Williams MS, Lubner S, Goldman FD. Chronic granulomatous disease presenting with disseminated intracranial aspergillosis. Pediatr. Blood Cancer 47 (1), 107-110 (2006).
41. Beauté J, Obenga G, Le Mignot L et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: A multicenter study in France. Pediatr. Infect. Dis. J. 30 (1), 57-62 (2011).
42. Martire B, Rondelli R, Soresina A et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: An Italian multicenter study. Clin. Immunol. 126 (2), 155-164 (2008).
43. Blumental S, Mouy R, Mahlaoui N et al. Invasive mold infections in chronic granulomatous disease: A 25 year retrospective survey. Clin. Infect. Dis. 53 (12), e159-e169 (2011).
44. Adinoff AD, Johnston RB, Aerobiologia, Dolen J, South MA. Chronic granulomatous disease and Pneumocystis carinii pneumonia. Pediatrics 69 (1), 133-134 (1982).
45. Pedersen FK, Johansen KS, Rosenkvist J, Tygstrup I, Valerius NH. Refractory Pneumocystis carinii infection in chronic granulomatous disease: Successful treatment with granulocytes. Pediatrics 64 (6), 935-938 (1979).
46. Allen DM, Chng HH. Disseminated Mycobacterium flavescens in a probable case of chronic granulomatous disease. J. Infect. 26 (1), 83-86 (1993).
47. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79 (3), 170-200 (2000).
48. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: Comparison of Aspergillus nidulans and Aspergillus fumigatus. Int. J. Infect. Dis. 8 (2), 103-110 (2004).
49. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77 (5), 345-354 (1998).
50. Vinh DC, Shea YR, Sugui JA et al. Invasive aspergillosis due to Neosartorya udagawae. Clin. Infect. Dis. 49 (1), 102-111 (2009).
51. Bellis G, Cazes MH, Parant A et al. Cystic fibrosis mortality trends in France. J. Cyst. Fibros. 6 (3), 179-186 (2007).
52. Girodon E, Cazeneuve C, Lebargy F et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur. J. Hum. Genet. 5 (3), 149-155 (1997).
53. Bobadilla JL, Macek M, Aerobiologia, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19 (6), 575-606 (2002).
54. Saiman L. Infection prevention and control in cystic fibrosis. Curr. Opin. Infect. Dis. 24 (4), 390-395 (2011).
55. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137 (1), 171-176 (2010).
56. Pihet M, Carrère J, Cimon B et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - a review. Med. Mycol. 47 (4), 387-397 (2009).
57. Lebecque P, Leonard A, Huang D et al. Exophiala (Wangiella) dermatitidis and cystic fibrosis - prevalence and risk factors. Med. Mycol. 48 (Suppl. 1), S4-S9 (2010).
58. Cimon B, Carrère J, Chazalette JP, Vinatier JF, Chabasse D, Bouchara JP. Chronic airway colonization by Penicillium emersonii in a patient with cystic fibrosis. Med. Mycol. 37 (4), 291-293 (1999).
59. de Valk HA, Klaassen CH, Yntema JB et al. Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J. Cyst. Fibros. 8 (2), 110-114 (2009).
60. Vanhee LM, Symoens F, Bouchara JP, Nelis HJ, Coenye T. High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonised patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 27 (10), 1005-1007 (2008).
61. Defontaine A, Zouhair R, Cimon B et al. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J. Clin. Microbiol. 40 (6), 2108-2114 (2002).
62. Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J. Intern. Med. 272 (6), 541-561 (2012).
63. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J. Med. Microbiol. 62 (Pt 1), 10-24 (2013).
64. Høiby N, Ciofu O, Johansen HK et al. The clinical impact of bacterial biofilms. Int. J. Oral. Sci. 3 (2), 55-65 (2011).
65. Hogan DA, Kolter R. Pseudomonas-Candida interactions: An ecological role for virulence factors. Science 296 (5576), 2229-2232 (2002).
66. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol. Microbiol. 54 (5), 1212-1223 (2004).
67. Mowat E, Rajendran R, Williams C et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol. Lett. 313 (2), 96-102 (2010).
68. Schoch CL, Seifert KA, Huhndorf S et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc. Natl. Acad. Sci. USA 109 (16), 6241-6246 (2012).
69. Houbraken J, Frisvad JC, Samson RA. Taxonomy of Penicillium section Citrina. Stud. Mycol. 70 (1), 53-138 (2011).
70. Varga J, Frisvad JC, Kocsubé S et al. New and revisited species in Aspergillus section. Nigri. Stud. Mycol. 69 (1), 1-17 (2011).
71. Ziska L, Caulfield F. The potential influence of rising atmospheric carbon dioxide (CO2) on public health: Pollen production of common ragweed as a test case. World Resource Rev. 12, 449-457 (2000).
72. Frenguelli G. Interactions between climatic changes and allergenic plants. Monaldi Arch. Chest Dis. 57 (2), 141-143 (2002).
73. D'Amato G, Liccardi G, D'Amato M, Cazzola M. Outdoor air pollution, climatic changes and allergic bronchial asthma. Eur. Respir. J. 20 (3), 763-776 (2002).
74. Corden J, Millington W. The long-term trends and seasonal variation of the aeroallergen Alternaria in Derby, UK. Aerobiologia, 17 (2), 127-136 (2001).
75. Harvell CD, Mitchell CE, Ward JR et al. Climate warming and disease risks for terrestrial and marine biota. Science 296 (5576), 2158-2162 (2002).
76. Yaguchi T, Someya A, Nihimura K. Two new species of Talaromyces from Taiwan and Japan. Mycoscience 35 (3), 249-255 (1994).
77. Cizkova D, Srutka P, Kolarik M, Kubatova A, Pazoutova S. Assessing the pathogenic effect of Fusarium, Geosmithia and Ophiostoma fungi from broad-leaved trees. Folia Microbiol. (Praha) 50 (1), 59-62 (2005).
78. Kolarik M, Freeland E, Utley C, Tisserat N. Geosmithia morbida sp. nov., a new phytopathogenic species living in symbiosis with the walnut twig beetle (Pityophtorus juglandis) on Juglans in USA. Mycologia 103 (2), 325-332 (2011).
79. Bastian F, Alabouvette C, Saiz-Jimenez C. The impact of arthropods on fungal community structure in Lascaux Cave. J. Appl. Microbiol. 106 (5), 1456-1462 (2009).